Condition: Hodgkin Disease · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30+ Anaplastic Large Cell Lymphoma · Sponsor: Medical College of Wisconsin
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).
This description comes directly from the study's public registry record.
Medical College of Wisconsin Cancer Center Clinical Trials Office · 866-680-0505 · cccto@mcw.edu
Medical College of Wisconsin Cancer Center Clinical Trials Office, MD · 866-680-0505 · cccto@mcw.edu
Always discuss trial participation with your own doctor first.
| Froedtert & the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05544968